Technology | November 02, 2011

Low Dose Molecular Breast Imaging Aids Tumor Detection

Gamma Medica Inc. will demonstrate the LumaGEM Low Dose Molecular Breast Imaging (MBI) System at RSNA 2012. 

LumaGEM MBI is the first commercially available, U.S. Food and Drug Administration (FDA)-cleared, planar, dual-head, fully solid state digital imaging system utilizing cadmium zinc telluride (CZT) technology used for digital breast imaging.  LumaGEM Low Dose MBI is a major advancement in the area of molecular imaging, identifying tumors in dense breast tissue that are often not visible with mammography. 

A 2011 publication in Radiology (doi:10.1148/radiol.10100625), documented the addition of molecular breast imaging (MBI) in 1,000 patients, following an injection of 20 mCi Tc-99m sestamibi, to screening mammography (MG) significantly increased detection of breast cancer in dense breasts from 27 percent with MG alone to 91 percent with the combination (p=0.016).

After implementing modifications that permit further radiation dose reduction, performance has been clinically compared between screen mammography and prevalent screen low-dose MBI in 2,400 women with dense breasts using an 8 mCi injection of Tc-99m sestamibi, dual-head CZT detectors by Gamma Medica, and acquired in dynamic frames to allow the generation of 4 mCi equivalent images.

For more information: www.gammamedica.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Densitas Enters Platform Partnership With Blackford
News | Breast Density | December 19, 2018
Breast imaging analytics company Densitas Inc. announced the signing of a new Alliance Partner Agreement with Blackford...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...